Aktis Oncology Plans $840 Million IPO Amid Biotech Market Recovery
Aktis Oncology, a Boston-based biotech firm, has announced plans for a U.S. IPO targeting a valuation of up to $840 million. The company aims to raise approximately $212 million by offering 11.8 million shares priced between $16 and $18 each. This move reflects renewed investor interest in the biotech sector.
Insights:
Aktis Oncology , a biotechnology company based in Boston, has announced its intention to launch an initial public offering (IPO) in the United States, seeking a valuation of up to $840 million. The company plans to raise approximately $212 million by offering 11.8 million shares priced between $16 and $18 each. This move comes as the biotech sector experiences a resurgence in investor interest following record-high IPO activity in 2025.
